Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

• Regeneron Pharmaceuticals, Inc. recently delivered a significant earnings beat, reporting actual EPS of $14.29 against a consensus estimate of $10.16 for the quarter ended July 30, 2026, while also exceeding revenue expectations with $4.29 billion in sales compared to the $3.82 billion consensus, demonstrating strong fundamental performance.
• The company's EYLEA HD product is gaining substantial market momentum, representing roughly 60% of the EYLEA franchise net sales in the second quarter and becoming the only innovative brand in its category to gain market share, driven by new label enhancements that allow for every-four-week dosing flexibility.
• Regeneron Pharmaceuticals, Inc. is currently trading at $801.82, a price point that sits below its 52-week high of $859.34 and aligns closely with the current analyst consensus price target of $800.36, suggesting the stock may be fairly valued relative to its recent performance and institutional support.
• Institutional investors are showing renewed confidence in the stock, with State Street Corp increasing its holdings by 3.6% in the second quarter and BlackRock Inc. establishing a new position worth approximately $5.68 billion, indicating strong backing from major financial entities.
• The company has strengthened its balance sheet by paying off its Sanofi development balance during the second quarter, a move that is expected to lift earnings from the collaboration beginning in the third quarter, thereby improving the profit share from its key Dupixent partnership.